Hong Kong stocks of innovative drug concept stocks fell collectively, Zaiding Pharmaceutical (09688.HK) fell more than 11%, Hengrui Pharmaceutical (01276.HK), Goree Pharmaceutical (01672.HK), Genting Xinyao (01952.HK) fell more than 5%, WuXi AppTec (02359.HK) fell more than 4%, Cinda Biological (01801.HK), WuXi Ming United (02268.HK), Hansen Pharmaceutical (03692.HK) fell more than 3%.
港股创新药概念股集体下跌,再鼎医药(09688.HK)跌超11%,恒瑞医药(01276.HK)、歌礼制药(01672.HK)、云顶新耀(01952.HK)跌超5%,药明康德(02359.HK)跌超4%,信达生物(01801.HK)、药明合联(02268.HK)、翰森制药(03692.HK)跌超3%。
Hong Kong stocks biomedical concept continued to decline in the afternoon, Tiger medicine (03347.HK) fell more than 6%, Junshi Biosciences (01877.HK), WuXi PharmaTech (02359.HK), Zaiding medicine (09688.HK), BeiGene (06160.HK) and other stocks fell.
Hong Kong biomedical plate early strong, Zaiding medicine (09688.HK) rose more than 12%, Junshi Biosciences (01877.HK) rose more than 5%, BeiGene (06160.HK), WuXi PharmaTech (02359.HK) and so on up.
港股生物医药板块盘初走强,再鼎医药(09688.HK)涨超12%,君实生物(01877.HK)涨超5%,百济神州(06160.HK)、药明康德(02359.HK)等跟涨。
Hong Kong stocks of biopharmaceutical stocks rose in the intraday, Kingsry biotechnology (01548.HK) rose more than 11%, Zaiding medicine (09688.HK) rose more than 10%, Lepu biological (02157.HK) rose nearly 10%, Yasheng medicine (06855.HK), Rongchang biological (09995.HK) rose more than 5%.